Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated opportunity, stakeholders in the pharma industry have long been developing follow on products   Roots Analysis has announced the addition of the “Herceptin® Trastuzumab Biosimilars Pipeline Review and Partnerships” report...